\
            
             &
            
        
    
            Contact us
        
This was 10 months ago
LocationNieuwegein, The Netherlands
The Netherlands Enterprise Agency organises a Digital & Health Matchmaking event to support stakeholders across Europe to connect, collaborate, and innovate. Set against the backdrop of our evolving digital landscape, this event will focus on discussing topics of the digital and health clusters for 2025 in Horizon Europe and Digital Europe, latest breakthrough developments in the intersection of the fields and provides ample room for connecting with relevant stakeholders.
In addition to the event, an online matchmaking platform will be launched to allow participants and other interested parties to connect, collaborate, and continue discussions after the event.
More information on the event and the matchmaking platform and the registration form can be found on this website.
                We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020). 
                Stay informed about what matters to you.
                By signing up, you can opt in for e-mail notifications and get access to
                a personalised dashboard that groups all news updates and event announcements in your domain(s).
            
Only for stakeholders located in Flanders
                        
                    The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.